🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "huge turning point" in the battle against increasingly resistant strains of the pathogen, according to researchers.

A Worldwide Health Concern

The sexually transmitted infection are increasing globally, with figures suggesting more than 82 million instances each year. Especially elevated rates are observed in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune development in the context of growing infection rates, increasing antimicrobial resistance and the extremely scarce therapeutic options currently available.”

Health officials are particularly alarmed about the increase in treatment-resistant strains. The WHO has listed it as a "critical concern". A tracking program found that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Treatment Options Receive Clearance

One new antibiotic, also known as Nuzolvence, was cleared by the US FDA in December for treating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Researchers anticipate that specific application of this new drug will help delay the development of resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, gained clearance in close succession. This medication, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This milestone marks a major breakthrough in the management of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Results and Worldwide Availability

Based on findings released by a prominent scientific publication, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This places it at an equal footing with the typical regimen, which combines an injection and a pill. The study included hundreds of participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the rights to register and commercialise the drug in many regions with limited resources.

Clinicians treating patients have expressed optimism. Having a single-dose, oral treatment such as this is seen as a "revolutionary step" for gonorrhoea control. This is considered crucial to lessen the impact of the infection for patients and to halt the transmission of extremely resistant gonorrhoea globally.